7W9Q image
Entry Detail
PDB ID:
7W9Q
Title:
Crystal structure of V30M-TTR in complex with naringenin derivative-14
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2021-12-10
Release Date:
2022-12-14
Method Details:
Experimental Method:
Resolution:
1.60 Å
R-Value Free:
0.20
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 21 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Transthyretin
Chain IDs:A, B
Chain Length:159
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
Chlorinated Naringenin Analogues as Potential Inhibitors of Transthyretin Amyloidogenesis.
J.Med.Chem. 65 16218 16233 (2022)
PMID: 36472374 DOI: 10.1021/acs.jmedchem.2c00511

Abstact

Misfolding and aggregation of transthyretin are implicated in the fatal systemic disease known as transthyretin amyloidosis. Here, we report the development of a naringenin derivative bearing two chlorine atoms that will be efficacious for preventing aggregation of transthyretin in the eye. The amyloid inhibitory activity of the naringenin derivative was as strong as that of tafamidis, which is the first therapeutic agent targeting transthyretin in the plasma. X-ray crystal structures of the compounds in complex with transthyretin demonstrated that the naringenin derivative with one chlorine bound to the thyroxine-binding site of transthyretin in the forward mode and that the derivative with two chlorines bound to it in the reverse mode. An ex vivo competitive binding assay showed that naringenin derivatives exhibited more potent binding than tafamidis in the plasma. Furthermore, an in vivo pharmacokinetic study demonstrated that the dichlorinated derivative was significantly delivered to the eye.

Legend

Protein

Chemical

Disease

Primary Citation of related structures